JP
PBYI icon

John Paulson’s Puma Biotechnology PBYI Stock Holding History

John Paulson’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-27,500
Closed -$2.4M – 79
2017
Q2 		$2.4M Buy
27,500
+11,810
+75% +$661K 0.03% 91
2017
Q1 		$584K Hold
15,690
– – 0.01% 94
2016
Q4 		$482K Sell
15,690
-68,810
-81% -$2.98M 0.01% 96
2016
Q3 		$5.67M Sell
84,500
-61,300
-42% -$3.1M 0.06% 69
2016
Q2 		$4.34M Buy
145,800
+75,500
+107% +$2.36M 0.04% 67
2016
Q1 		$2.06M Buy
70,300
+24,300
+53% +$1.1M 0.02% 82
2015
Q4 		$3.61M Buy
+46,000
New +$3.61M 0.02% 60

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

John Paulson's PBYI Position: Q3 2017 in Review

John Paulson sold out of Puma Biotechnology (PBYI) in Q3 2017, closing a stake of 27,500 shares — an estimated $2.4M sold.

John Paulson first reported a position in PBYI in Q4 2015 and held it in 7 quarters. The position peaked at $5.67M in Q3 2016. 171 funds tracked by Wall St. Rank hold PBYI as of Q3 2017.

  • John Paulson reported no remaining Puma Biotechnology position as of Q3 2017 after selling out during the quarter.
  • John Paulson sold 27,500 Puma Biotechnology shares in Q3 2017, an estimated $2.4M.
  • John Paulson first reported a position in Puma Biotechnology in Q4 2015 and held it in 7 quarters.
  • John Paulson's Puma Biotechnology position peaked at $5.67M in Q3 2016.
  • 171 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.